ASLAN Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Corporate Update
August 13, 2019 04:03 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Aug. 13, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology and immunology focused biopharma company, today reported financial results for...
ASLAN Pharmaceuticals Signs New Agreement With Biogenetics for Commercialisation of ASLAN003 in South Korea
March 11, 2019 03:00 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, March 11, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global...
ASLAN Pharmaceuticals Announces Strategic Prioritisation of Clinical Development Programs and Corporate Restructuring
January 29, 2019 17:40 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Jan. 29, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global...
ASLAN Pharmaceuticals Announces IND Submission for ASLAN003 to U.S. FDA and Conclusion of 30-Day Review Period
January 04, 2019 02:00 ET
|
ASLAN Pharmaceuticals Limited
- ASLAN003 is an orally active, potent inhibitor of DHODH that has the potential to be first-in-class in AML- Positive interim Phase 2a data for ASLAN003 in AML was presented at the 2018 ASH Annual...
New Data on ASLAN003 Presented at Ash Annual Meeting Shows First Signs of Clinical Activity of a DHODH Inhibitor in Acute Myeloid Leukaemia
December 02, 2018 12:00 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Dec. 03, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
ASLAN Pharmaceuticals to Present New Data on ASLAN003 at American Society of Hematology Annual Meeting
November 01, 2018 10:20 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Nov. 01, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...
ASLAN Pharmaceuticals to Present Posters on Varlitinib and ASLAN003 at European Society for Medical Oncology Congress
October 09, 2018 06:15 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Oct. 09, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (ASLAN, 6497.TT, Nasdaq: ASLN), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia...
ASLAN Pharmaceuticals Granted Orphan Drug Designation by the FDA for ASLAN003 for the Treatment of Acute Myeloid Leukaemia
August 20, 2018 02:49 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, Aug. 20, 2018 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company targeting cancers that are both highly prevalent in Asia and...